Value of caveolin‑1 in cancer progression and prognosis: Emphasis on cancer‑associated fibroblasts, human cancer cells and mechanism of caveolin‑1 expression (Review)

Chen,Dali; Che,Guowei

doi:10.3892/ol.2014.2385

Value of caveolin‑1 in cancer progression and prognosis: Emphasis on cancer‑associated fibroblasts, human cancer cells and mechanism of caveolin‑1 expression (Review)

Authors:
- Dali Chen
- Guowei Che
View Affiliations

Affiliations: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: July 28, 2014 https://doi.org/10.3892/ol.2014.2385
Pages: 1409-1421

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Caveolin‑1 (Cav‑1) is found predominately in terminally differentiated cells, such as adipocytes, endothelia and smooth muscle cells, as well as type I pneumocytes. As a main structural component of caveolae, Cav‑1 is important in modulating cellular signaling. In the present study, the expression and clinical role of Cav‑1 were analyzed in tumor stromal and human cancer cells, respectively. The results of previous studies have shown that the downregulation of tumor stromal Cav‑1 promotes tumor survival and predicts a poor tumor prognosis, predominantly concentrating on the mechanism of the metabolism of the cancer microenvironment (according to the autophagic tumor stroma model of cancer metabolism and the reverse Warburg effect). However, contradictory results concerning the expression, clinical roles and associated mechanisms of Cav‑1 have been reported. An improved understanding of Cav‑1 expression in tumor stromal and cancer cells will increase knowledge with regard to the clinical value of Cav‑1 and its detailed mechanisms. This review summarizes the novel data concerning the clinical values and probable mechanisms of Cav‑1 expression in tumor stromal (predominantly in cancer‑associated fibroblasts) and cancer cells, respectively.

View Figures

View References

1	Palade GE: Fine structure of blood capillaries. J Appl Phys. 24:1424–1436. 1953.
2	Glenney JR Jr and Zokas L: Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. 108:2401–2408. 1989.
3	Sowa G, Pypaert M, Fulton D and Sessa WC: The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-1-dependent caveolae formation. Proc Natl Acad Sci USA. 100:6511–6516. 2003.
4	Song KS, Scherer PE, Tang Z, et al: Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 271:15160–15165. 1996.
5	Razani B, Combs TP, Wang XB, et al: Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 277:8635–8647. 2002.
6	Rothberg KG, Heuser JE, Donzell WC, et al: Caveolin, a protein component of caveolae membrane coats. Cell. 68:673–682. 1992.
7	Engelman JA, Zhang XL and Lisanti MP: Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5′ promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett. 448:221–230. 1999.
8	Kurzchalia T, Dupree P, Parton RG, et al: VIP 21, A 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J Cell Biol. 118:1003–1014. 1992.
9	Glenney JR: The sequence of human caveolin reveals identity with VIP 21, a component of transport vesicles. FEBS Lett. 314:45–48. 1992.
10	Monier S, Parton RG, Vogel F, et al: VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell. 6:911–927. 1995.
11	Arbuzova A, Wang L, Wang J, et al: Membrane binding of peptides containing both basic and aromatic residues. Experimental studies with peptides corresponding to the scaffolding region of caveolin and the effector region of MARCKS. Biochemistry. 39:10330–10339. 2000.
12	Luetterforst R, Stang E, Zorzi N, et al: Molecular characterization of caveolin association with the Golgi complex: identification of a cis-Golgi targeting domain in the caveolin molecule. J Cell Biol. 145:1443–1459. 1999.
13	Schlegel A and Lisanti MP: A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem. 275:21605–21617. 2000.
14	Schlegel A, Schwab R, Scherer PE, et al: A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J Biol Chem. 274:22660–22667. 1999.
15	Sargiacomo M, Scherer PE, Tang ZL, et al: Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc Natl Acad Sci USA. 92:9407–9411. 1995.
16	Couet J, Li S, Okamoto T, et al: Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolaeassociated proteins. J Biol Chem. 272:6525–6533. 1997.
17	Dvorak HF, Weaver VM, Tlsty TD, et al: Tumor microenvironment and progression. J Surg Oncol. 103:468–474. 2011.
18	Chun TH, Hotary, et al: A pericellular collagenase directs the 3-dimensional development of while adipose tissue. Cell. 125:577–591. 2006.
19	Kan S, Konishi E, Arita T, et al: Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma. J Cutan Pathol. Mar 3–2014.(Epub ahead of print).
20	Zhou B, Chen WL, Wang YY, et al: A role for cancer-associated fibroblasts in inducing the epithelial-to-mesenchymal transition in human tongue squamous cell carcinoma. J Oral Pathol Med. Mar 20–2014.(Epub ahead of print).
21	Yu Y, Lee JS, Xie N, et al: Prostate stromal cells express the progesterone receptor to control cancer cell mobility. PLoS One. 9:e927142014.
22	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006.
23	De Wever O, Demetter P, Mareel M and Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 123:2229–2238. 2008.
24	Sugimoto H, Mundel TM, Kieran MW and Kalluri R: Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 5:1640–1646. 2006.
25	Erez N, Truitt M, Olson P, et al: Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 17:135–147. 2010.
26	Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15:275–286. 2004.
27	Koleske AJ, Baltimore D and Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA. 92:1381–1385. 1995.
28	Mercier I, Casimiro MC, Wang C, et al: Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation. Cancer Biol Ther. 7:1212–1225. 2008.
29	Sotgia F, Del Galdo F, Casimiro MC, et al: Caveolin-1−/− null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol. 174:746–761. 2009.
30	Sloan EK, Ciocca DR, Pouliot N, et al: Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol. 174:2053–2043. 2009.
31	El-Gendi SM, Mostafa MF and El-Gendi AM: Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res. 18:459–69. 2012.
32	Witkiewicz AZ, Dasgupta A, Sammons S, et al: Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther. 10:135–143. 2010.
33	Witkiewicz AK, Dasgupta A, Sotgia F, et al: An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 74:2023–2034. 2009.
34	Simpkins SA, Hanby AM, Holliday DL, et al: Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol. 227:490–498. 2012.
35	Zhao X, He Y, Gao J, et al: Caveolin-1 expression level in cancer associated fibroblasts predicts outcome in gastric cancer. PLoS One. 8:e591022013.
36	He Y, Zhao X, Gao J, et al: Quantum dots-based immunofluorescent imaging of stromal fibroblasts caveolin-1 and light chain 3B expression and identification of their clinical significance in human gastric cancer. Int J Mol Sci. 13:13764–13780. 2012.
37	Ayala G, Morello M, Frolov A, et al: Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 23:77–87. 2013.
38	Di Vizio D, Morello M, Sotgia F, et al: An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle. 8:2420–2424. 2009.
39	Wu KN, Queenan M, Brody JR, et al: Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle. 10:4250–5. 2011.
40	Witkiewicz AK, Kline J, Queenan M, et al: Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle. 10:1794–1809. 2011.
41	Pavlides S, Tsirigos A, Vera I, et al: Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the ‘reverse Warburg effect’: a transcriptional informatics analysis with validation. Cell Cycle. 9:2201–2219. 2010.
42	Bist A, Fielding CJ and Fielding PE: p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. Biochemistry. 39:1966–1972. 2000.
43	Mueller MM and Fusenig NE: Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 4:839–849. 2004.
44	Martinez-Outschoorn UE, Trimmer C, Lin Z, et al: Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB. Cell Cycle. 9:3515–3533. 2010.
45	Bartek J, Bartkova J and Lukas J: The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 8:805–14. 1996.
46	Usui I, Haruta T, Iwata M, et al: Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR pathway regulates adipocyte differentiation. Biochem Biophys Res Commun. 275:115–120. 2000.
47	Gao N, Flynn DC, Zhang Z, et al: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol. 287:C281–C291. 2004.
48	Xu Y, Chen SY, Ross KN, et al: Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 66:7783–7792. 2006.
49	Mercier I, Camacho J, Titchen K, et al: Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor anti-aging drug. Am J Path. 181:278–292. 2012.
50	Ong CT, Khoo YT, Mukhopadhyay A, et al: mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol. 16:394–404. 2007.
51	Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, et al: The autophagic tumor stroma model of cancer or ‘battery-operated tumor growth’: A simple solution to the autophagy paradox. Cell Cycle. 9:4297–4306. 2010.
52	Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, et al: Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 9:3256–3276. 2010.
53	Garcia-Cardena G, Martasek P, Masters BS, et al: Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem. 272:25437–40. 1997.
54	Pavlides S, Tsirigos A, Migneco G, et al: The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in feuling tumor cell metabolism. Cell Cycle. 9:3485–3505. 2010.
55	Trimmer C, Sotgia F, Whitaker-Menezes D, et al: Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther. 11:383–394. 2011.
56	Chiavarina B, Whitaker-Menezes D, Migneco F, et al: HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle. 9:3534–3551. 2010.
57	Capparelli C, Whitaker-Menezes D, Guido C, et al: CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle. 11:2272–2284. 2012.
58	Papandreou I, Cairns RA, Fontana L, et al: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3:187–97. 2006.
59	Salceda S and Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem. 272:22642–22647. 1997.
60	Guzy RD, Hoyos B, Robin E, et al: Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1:401–8. 2005.
61	Schofield CJ and Ratcliffe PJ: Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 338:617–626. 2005.
62	Valko M, Rhodes CJ, Moncol J, et al: Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 160:1–40. 2006.
63	Pantuck AJ, An J, Liu H, et al: NFkappaBdependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 70:752–61. 2010.
64	Jung Y, Isaacs JS, Lee S, et al: Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappaB activation. Biochem J. 370:1011–1017. 2003.
65	Robinson JM and Gibbs M: Photosynthetic intermediates, the warburg effect, and glycolate synthesis in isolated spinach chloroplasts. Plant Physiol. 53:790–797. 1974.
66	Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al: The reverse Warburg effect Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 8:3984–4001. 2009.
67	Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, et al: Using the ‘reverse Warburg effect’ to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle. 11:1108–1117. 2012.
68	Fernandez MA, Albor C, Ingelmo-Torres M, et al: Caveolin-1 is essential for liver regeneration. Science. 313:1628–1632. 2006.
69	Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009.
70	Fogal V, Richardson AD, Karmali PP, et al: Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol. 30:1303–1318. 2010.
71	Elsheikh SE, Green AR, Rakha EA, et al: Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer. 99:327–334. 2008.
72	Zuccari DAPC, Castro1 R, Gavioli AF, et al: Immunohistochemical and molecular analysis of caveolin-1 expression in canine mammary tumors. Genet Mol Res. 11:153–165. 2012.
73	Sagara Y, Mimori K, Yoshinaga K, et al: Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer. 91:959–965. 2004.
74	Gao X, Sun Y, Huang L, et al: Down-regulation of caveolin-1 in gastric carcinoma and its clinical biological significance. Ai Zheng. 24:311–316. 2005.(In Chinese).
75	Yan J, Lu Q, Cai L, et al: Expression of caveolin-1 gene in hepatitis B-related hepatocellular carcinoma and the clinical significance thereof. Zhonghua Yi Xue Za Zhi. 88:3272–3274. 2008.(In Chinese).
76	Shi L, Chen XM, Wang L, et al: Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density, and clinical outcome. Cancer. 109:1523–1531. 2007.
77	Ando T, Ishiguro H, Kimura M, et al: The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep. 18:601–609. 2007.
78	Yan J, Lu Q, Cai L, et al: Expression of caveolin-1 gene in hepatitis B-related hepatocellular carcinoma and the clinical significance thereof. Zhonghua Yi Xue Za Zhi. 88:3272–3274. 2008.
79	Tanase CP, Dima S, Mihai M, et al: Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Histol. 40:23–29. 2009.
80	Cho DS, Yim H, Cho KS, et al: Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract. J Korean Med Sci. 23:296–301. 2008.
81	Yang G, Timme TL, Frolov A, et al: Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 103:1186–1194. 2005.
82	Joshi B, Strugnell SS, Goetz JG, et al: Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 68:8210–8220. 2008.
83	Savage K, Lambros MB, Robertson D, et al: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 13:90–101. 2007.
84	Nam KH, Lee BL, Park JH, et al: Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression ingastric cancer. Pathobiology. 80:87–94. 2013.
85	Tang Y, Zeng X, He F, et al: Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. Med Oncol. 29:977–984. 2012.
86	Tse EY, Ko FC, Tung EK, et al: Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol. 226:645–653. 2012.
87	Hung KF, Lin SC, Liu CJ, et al: The biphasic differential expression of the cellular membrane protein, caveolin-1, in oral carcinogenesis. J Oral Pathol Med. 32:461–467. 2003.
88	Suzuoki M, Miyamoto M, Kato K, et al: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer. 87:1140–1144. 2002.
89	Waalkes S, Eggers H, Blasig H, et al: Caveolin 1 mRNA is overexpressed in malignant renal tissue and might serve as a novel diagnostic marker for renal cancer. Biomark Med. 5:219–225. 2011.
90	Davidson B, Nesland JM, Goldberg I, et al: Caveolin-1 expression in advanced-stage ovarian carcinoma-a clinicopathologic study. Gynecol Oncol. 81:166–171. 2001.
91	Liu HX, Xing LX, Wang HB, et al: Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer. Zhonghua Bing Li Xue Za Zhi. 37:615–619. 2008.(In Chinese).
92	Zhang YX, Chen HL, Ye B, et al: Study on expression and methylation of caveolin 1 gene in non-small cell lung cancers. Zhonghua Bing Li Xue Za Zhi. 37:300–304. 2008.(In Chinese).
93	Witkiewicz AK, Nguyen KH, Dasgupta A, et al: Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome. Cell Cycle. 7:3021–3025. 2008.
94	Campbell L, Gumbleton M and Griffiths DFR: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 89:1909–1913. 2003.
95	Steffens Sandra, Schrader Andres J, Blasig Hanna, et al: Caveolin 1 protein expression in renal cell carcinoma predicts survival. BMC Urology. 11:252011.
96	Campbell L, Jasani B, Edwards K, et al: Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer. 98:931–940. 2008.
97	Joo HJ, Oh DK, Kim YS, et al: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poorprognosis in clear cell renal cell carcinoma. BJU Int. 93:291–296. 2004.
98	Phuoc NB, Ehara H, Gotoh T, et al: Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cellrenal cell carcinoma. Urology. 69:843–848. 2007.
99	Zhang ZB, Cai L, Zheng SG, et al: Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res. 15:495–502. 2009.
100	Yu JH, Wei Q, Qi FJ, et al: Significance of caveolin-1 expression in primary lung cancer. Zhonghua Bing Li Xue Za Zhi. 35:664–668. 2006.
101	Ho Chao-Chi, Huang Pei-Hsin, Huang Hsin-Yi, et al: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 161:1647–1656. 2002.
102	Zhan P, Shen XK, Qian Q, et al: Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas. Oncol Rep. 27:1072–1078. 2012.
103	Yoo SH, Park YS, Kim HR, et al: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer. 42:195–202. 2003.
104	Moon KC, Lee GK, Yoo SH, et al: Expression of caveolin-1 in pleomorphic carcinoma of the lung is correlated with a poor prognosis. Anticancer Res. 25:4631–467. 2005.
105	Ho CC, Kuo SH, Huang PH, et al: Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 59:105–110. 2008.
106	Yang G, Truong LD, Wheeler TM and Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59:5719–5723. 1999.
107	Satoh T, Yang G, Egawa S, et al: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer. 97:1225–1233. 2003.
108	Gumulec J, Sochor J, Hlavna M, et al: Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncol Rep. 27:831–841. 2012.
109	Karam JA, Lotan Y, Roehrborn CG, et al: Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate. 67:614–22. 2007.
110	Yang G, Goltsov AA, Ren C, et al: Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res. 10:218–229. 2012.
111	Steiner I, Jung K, Miller K, et al: Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. Oncol Rep. 27:389–395. 2012.
112	Tahir SA, Ren C, Timme TL, et al: Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 9:3653–3659. 2003.
113	Sugie S, Tsukino H, Yamauchi T, et al: Functional polymorphism in the CAV1 T29107A gene and its association with prostate cancer risk among Japanese men. Anticancer Res. 33:1023–1027. 2013.
114	Langeberg WJ, Tahir SA, Feng Z, et al: Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes. Prostate. 70:1020–1035. 2010.
115	Barresi V, Giuffre’ G, Vitarelli E, et al: Caveolin-1 immuno-expression in human gastric cancer: histopathogenetic hypotheses. Virchows Arch. 453:571–578. 2008.
116	Sotgia F, Williams TM, Schubert W, et al: Caveolin-1 deficiency (−/−) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol. 168:292–309. 2006.
117	Cantiani L, Manara MC, Zucchini C, et al: Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res. 67:7675–7685. 2007.
118	Senetta R, Miracco C, Lanzafame S, et al: Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes. Neuro Oncol. 13:176–183. 2011.
119	Ruan J and Weng ZL: Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma. Zhonghua Zhong Liu Za Zhi. 32:429–431. 2010.(In Chinese).
120	Qayyum T, Fyffe G, Duncan M, et al: The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br J Cancer. 13; 106:1187–1195. 2012.
121	Du ZM, Hu CF, Shao Q, et al: Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 125:1832–1841. 2009.
122	Rödel F, Capalbo G, Rödel C, et al: Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy inrectal cancer. Int J Radiat Oncol Biol Phys. 73:846–852. 2009.
123	Wu HC, Chang CH, Tsou YA, et al: Significant association of caveolin-1 (CAV1) genotypes with prostate cancer susceptibility in Taiwan. Anticancer Res. 31:745–749. 2011.
124	Tsou YA, Tsai CW, Tsai MH, et al: Association of caveolin-1 genotypes with nasopharyngeal carcinoma susceptibility in Taiwan. Anticancer Res. 31:3629–3632. 2011.
125	Syeed N, Hussain F, Husain SA, et al: 5′-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir. Asian Pac J Cancer Prev. 13:371–375. 2012.
126	Shajahan AN, Goel S, de Assis S, et al: Changes in mammary caveolin-1 signaling pathways are associated with breast cancer risk in rats exposed to estradiol in utero or during prepuberty. Horm Mol Biol Clin Investig. 2:227–234. 2010.
127	Lin M, DiVito MM, Merajver SD, et al: Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and caveolin-1. Mol Cancer. 4:212005.
128	Thomas S, Overdevest JB, Nitz MD, et al: Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladdercancer. Cancer Res. 71:832–841. 2011.
129	Arpaia E, Blaser H, Quintela-Fandino M, et al: The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 31:884–896. 2012.
130	Chiu WT, Lee HT, Huang FJ, et al: Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res. 71:4932–4943. 2011.
131	Zhang H, Su L, Müller S, et al: Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cellcarcinoma. Br J Cancer. 99:1684–1694. 2008.
132	Yeh D, Chen C, Sun MZ, et al: Caveolin-1 is an important factor for the metastasis and proliferation of human small cell lung cancer NCI-H446cell. Anat Rec (Hoboken). 292:1584–1592. 2009.
133	Urra H, Torres VA, Ortiz RJ, et al: Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear inmetastatic cancer cells. PLoS One. 7:e330852012.
134	Duxbury MS, Ito H, Ashley SW, et al: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation inBxPC3 pancreatic adenocarcinoma cells. J Biol Chem. 279:23176–82. 2004.
135	Meyer C, Liu Y, Kaul A, et al: Caveolin-1 abrogates TGF-β mediated hepatocyte apoptosis. Cell Death Dis. 4:e4662013.
136	Katsogiannou M, El Boustany C, Gackiere F, et al: Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One. 4:e70682009.
137	Rodriguez DA, Tapia JC, Fernandez JG, et al: Caveolin-1-mediated suppression of cyclooxygenase-2 via a beta-catenin-Tcf/Lef-dependent transcriptional mechanism reduced prostaglandin E2 production and survivin expression. Mol Biol Cell. 20:2297–2310. 2009.
138	Palozza P, Sestito R, Picci N, et al: The sensitivity to beta-carotene growth-inhibitory and proapoptotic effects is regulated by caveolin-1 expression in human colon and prostate cancer cells. Carcinogenesis. 29:2153–2161. 2008.